Filing Flows › Insight Molecular Diagnostics (IMDX) › Recalls, complaints & regulation
Insight Molecular Diagnostics (IMDX): clinical trials
Insight Molecular Diagnostics (IMDX) beyond its filings: 2 active clinical trials.
Insight Molecular Diagnostics' latest quarter
Insight Molecular Diagnostics, Q2 2026: revenue $239K (-54% year over year), net loss $11.3M, operating cash flow −$9.3M. The chart follows the revenue to costs, profit and cash.
Questions
How many clinical trials does Insight Molecular Diagnostics have?
2 active studies on ClinicalTrials.gov, 0 in phase 3.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.